Bethge, Wolfgang Andreas 
; Martus, Peter ; Schmitt, Michael ; Holtick, Udo ; Subklewe, Marion ; von Tresckow, Bastian ; Ayuk, Francis ; Wagner-Drouet, Eva Maria ; Wulf, Gerald G ; Marks, Reinhard ; Penack, Olaf ; Schnetzke, Ulf ; Koenecke, Christian ; von Bonin, Malte ; Stelljes, Matthias ; Glass, Bertram ; Baldus, Claudia D ; Vucinic, Vladan ; Mougiakakos, Dimitrios ; Topp, Max S ; Fante, Matthias Alexander ; Schroers, Roland ; Bayir, Lale May ; Borchmann, Peter ; Buecklein, Veit ; Hanoun, Christine ; Thomas, Simone ; Beelen, Dietrich W. ; Lengerke, Claudia ; Kroeger, Nicolaus ; Dreger, Peter ;
; Martus, Peter ; Schmitt, Michael ; Holtick, Udo ; Subklewe, Marion ; von Tresckow, Bastian ; Ayuk, Francis ; Wagner-Drouet, Eva Maria ; Wulf, Gerald G ; Marks, Reinhard ; Penack, Olaf ; Schnetzke, Ulf ; Koenecke, Christian ; von Bonin, Malte ; Stelljes, Matthias ; Glass, Bertram ; Baldus, Claudia D ; Vucinic, Vladan ; Mougiakakos, Dimitrios ; Topp, Max S ; Fante, Matthias Alexander ; Schroers, Roland ; Bayir, Lale May ; Borchmann, Peter ; Buecklein, Veit ; Hanoun, Christine ; Thomas, Simone ; Beelen, Dietrich W. ; Lengerke, Claudia ; Kroeger, Nicolaus ; Dreger, Peter ; 
Abstract
CD19-directed chimeric antigen receptor (CAR) T cells have evolved as a new standard-of-care (SOC) treatment in patients with relapsed/refractory (r/r) large B-cell lymphoma (LBCL). Here, we report the first German real-world data on SOC CAR T-cell therapies with the aim to explore risk factors associated with outcomes. Patients who received SOC axicabtagene ciloleucel (axi-cel) or ...
Owner only: item control page
Altmetric